Market Summary
USD131.19-1.88
Market Closed-1.41%
JAZZ Stock Price
JAZZ RSI Chart
JAZZ Valuation
JAZZ Price/Sales (Trailing)
JAZZ Profitability
JAZZ Fundamentals
JAZZ Revenue
JAZZ Earnings
Price Action
52 Week Range
120.64160.96
(Low)(High)
Last 7 days
0.9%
Last 30 days
-5.8%
Last 90 days
8.6%
Trailing 12 Months
4.6%
JAZZ Financial Health
JAZZ Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for JAZZ
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-01 | Patil Neena M | sold | -216,375 | 144 | -1,500 | evp & chief legal officer |
2023-08-29 | Carr Patricia | sold | -20,372 | 143 | -142 | svp, chief accounting officer |
2023-08-15 | Patil Neena M | sold | -104,695 | 139 | -750 | evp & chief legal officer |
2023-08-14 | Smith Mark Douglas | sold | -171,454 | 138 | -1,241 | - |
2023-08-14 | Sohn Catherine A. | sold | -171,455 | 138 | -1,241 | - |
2023-08-14 | Winningham Rick E | sold | -171,455 | 138 | -1,241 | - |
2023-08-14 | Cook Jennifer E. | sold | -171,454 | 138 | -1,241 | - |
2023-08-14 | Carr Patricia | sold | -21,828 | 138 | -158 | svp, chief accounting officer |
2023-08-14 | ENRIGHT PATRICK G | sold | -171,455 | 138 | -1,241 | - |
2023-08-14 | McSharry Heather Ann | sold | -185,685 | 138 | -1,344 | - |
Which funds bought or sold JAZZ recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | added | 35.77 | 1,467,000 | 11,222,000 | 0.01% |
2023-09-12 | Farther Finance Advisors, LLC | added | 11.54 | -210 | 3,595 | -% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 40,166 | 40,166 | -% |
2023-09-06 | Deep Track Capital, LP | added | 4.17 | -20,633,500 | 154,962,000 | 7.17% |
2023-08-28 | DELPHI MANAGEMENT INC /MA/ | new | - | 1,264,000 | 1,264,000 | 1.31% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | unchanged | - | -2,396,990 | 13,289,600 | 0.13% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -4.93 | -3,040,980 | 12,585,300 | 0.02% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 2.98 | -2,987,000 | 20,418,000 | 0.20% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -10.71 | -435,979 | 1,354,260 | -% |
2023-08-17 | Orion Portfolio Solutions, LLC | reduced | -2.97 | -640,844 | 2,960,780 | 0.03% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Jazz Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Sep 11, 2023 | vanguard group inc | 10.26% | 6,479,474 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.61% | 6,050,625 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 10.6% | 6,652,382 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 10.6% | 6,652,382 | SC 13G | |
| Jan 05, 2023 | jpmorgan chase & co | 4.6% | 2,924,604 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Jan 28, 2022 | blackrock inc. | 10.5% | 6,450,368 | SC 13G/A | |
| Jan 24, 2022 | jpmorgan chase & co | 5.2% | 3,248,156 | SC 13G | |
| Feb 11, 2021 | renaissance technologies llc | 5.56% | 3,099,050 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.76% | 4,877,893 | SC 13G/A |
Recent SEC filings of Jazz Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 12, 2023 | 8-K | Current Report | |
| Sep 11, 2023 | SC 13G/A | Major Ownership Report | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 01, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 31, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 17, 2023 | 4 | Insider Trading | |
| Aug 15, 2023 | 4 | Insider Trading | |
| Aug 15, 2023 | 4 | Insider Trading | |
| Aug 15, 2023 | 4 | Insider Trading |
Peers (Alternatives to Jazz Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 494.8B | 29.5B | -0.66% | 79.36% | 76.16 | 16.77 | 1.53% | 14.16% |
JNJ | 413.2B | 97.8B | -4.35% | -2.72% | 31.65 | 4.23 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -4.37% | 23.96% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 182.9B | 77.9B | -10.94% | -25.44% | 8.52 | 2.35 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -5.70% | -15.91% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.99% | 679.20% | -74.1 | 4.1K | -86.94% | 71.24% |
PRGO | 4.3B | 4.6B | -16.08% | -16.44% | -62.89 | 0.92 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
SUPN | 1.6B | 634.0M | -6.94% | -10.23% | 36.56 | 2.5 | 0.62% | -24.59% |
TLRY | 1.6B | 627.1M | -7.75% | -11.11% | -1.08 | 2.51 | -0.20% | -204.67% |
INVA | 858.4M | 244.3M | -1.05% | 13.25% | 4.35 | 3.51 | -39.50% | -4.99% |
CRON | 804.1M | 109.5M | 24.85% | -25.44% | -5.6 | 7.34 | -2.66% | -32.13% |
CGC | 507.6M | 453.3M | 136.46% | -66.34% | -0.41 | 1.12 | -16.04% | 55.90% |
ACRS | 469.2M | 31.2M | -3.91% | -52.16% | -4.46 | 15.05 | 407.54% | -26.47% |
OCUL | 255.1M | 54.6M | -17.22% | -39.02% | -2.81 | 4.67 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Jazz Pharmaceuticals News
Returns for JAZZ
Cumulative Returns on JAZZ
4.0%
10-Year Cumulative Returns
0.8%
7-Year Cumulative Returns
-4.4%
5-Year Cumulative Returns
-1.6%
3-Year Cumulative Returns
Risks for JAZZ
What is the probability of a big loss on JAZZ?
78.8%
Probability that Jazz Pharmaceuticals stock will be more than 20% underwater in next one year
49.6%
Probability that Jazz Pharmaceuticals stock will be more than 30% underwater in next one year.
0%
Probability that Jazz Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does JAZZ drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Jazz Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Financials for Jazz Pharmaceuticals
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 0.7% | 3,762,904,000 | 3,738,465,000 | 3,659,374,000 | 3,583,982,000 | 3,481,445,000 | 3,300,378,000 | 3,094,238,000 | 2,863,024,000 | 2,625,797,000 | 2,436,422,000 | 2,363,567,000 | 2,279,790,000 | 2,216,604,000 | 2,188,301,000 | 2,161,761,000 | 2,056,478,000 | 1,988,149,000 | 1,954,495,000 | 1,890,922,000 | 1,850,864,000 | 1,793,346,000 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,276,084,000 | 1,279,876,000 | 1,324,681,000 |
| S&GA Expenses | -1.8% | 1,380,442,000 | 1,406,071,000 | 1,416,967,000 | 1,432,226,000 | 1,437,430,000 | 1,499,988,000 | 1,451,683,000 | 1,300,393,000 | 1,143,966,000 | 906,341,000 | 854,233,000 | 821,336,000 | 792,787,000 | 777,395,000 | 736,942,000 | 684,532,000 | 661,699,000 | 644,264,000 | 683,530,000 | 664,715,000 | 633,365,000 |
| R&D Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 299,726,000 | 259,001,000 | 230,306,000 | 224,054,000 | 226,616,000 | 235,954,000 | 232,156,000 |
| EBITDA | 100.0% | - | -23,078,000 | -71,811,000 | -47,336,000 | -54,661,000 | -122,761,000 | 3,762,000 | - | - | 714,883,000 | 369,895,000 | 245,457,000 | 191,526,000 | 204,190,000 | 528,702,000 | 650,892,000 | 705,784,000 | - | - | - | - |
| EBITDA Margin | 100.0% | - | -0.01 | -0.02 | -0.01 | -0.02 | -0.04 | 0.00 | - | - | 0.29 | 0.16 | 0.11 | 0.09 | 0.09 | 0.24 | 0.32 | 0.35 | - | - | - | - |
| Interest Expenses | - | - | - | 270,671,000 | - | - | - | 138,271,000 | - | - | - | 42,470,000 | - | - | - | 43,002,000 | - | - | - | 42,706,000 | - | - |
| Earnings Before Taxes | 18.8% | -263,238,000 | -324,008,000 | -372,784,000 | -77,621,000 | -85,125,000 | -242,199,000 | -112,838,000 | 76,797,000 | 312,571,000 | 620,083,000 | 275,095,000 | 171,057,000 | 117,126,000 | 129,790,000 | 454,302,000 | 578,992,000 | 633,884,000 | 579,199,000 | 529,463,000 | 482,931,000 | 378,868,000 |
| EBT Margin | 100.0% | - | -0.09 | -0.10 | -0.02 | -0.02 | -0.07 | -0.04 | 0.03 | 0.12 | 0.25 | 0.12 | 0.08 | 0.05 | 0.06 | 0.21 | - | - | - | - | - | - |
| Net Income | 44.6% | -86,514,000 | -156,287,000 | -224,060,000 | -18,687,000 | -51,872,000 | -449,853,000 | -329,668,000 | -160,903,000 | 40,164,000 | 518,281,000 | 238,616,000 | 179,194,000 | 133,236,000 | 280,333,000 | 523,367,000 | 608,845,000 | 655,885,000 | 486,308,000 | 447,098,000 | 519,835,000 | 434,045,000 |
| Net Income Margin | 100.0% | - | -0.04 | -0.06 | -0.01 | -0.01 | -0.14 | -0.11 | -0.06 | 0.02 | 0.21 | 0.10 | 0.08 | 0.06 | 0.13 | 0.24 | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 1,363,130,000 | 1,242,931,000 | 1,078,126,000 | 920,965,000 | 664,724,000 | 750,866,000 | 765,234,000 | 754,022,000 | 899,334,000 | 884,644,000 | 783,149,000 | 855,045,000 | 810,100,000 | 736,266,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 1.9% | 11,261 | 11,047 | 10,835 | 10,385 | 11,200 | 11,769 | 12,299 | 12,478 | 13,213 | 6,756 | 6,536 | 6,292 | 6,067 | 5,215 | 5,539 | 5,528 | 5,489 | 5,280 | 5,203 | 5,486 | 5,349 |
| Current Assets | 8.1% | 3,010 | 2,785 | 2,606 | 2,572 | 2,591 | 2,501 | 2,611 | 2,628 | 2,954 | 3,167 | 2,840 | 2,556 | 2,302 | 1,518 | 1,630 | 1,521 | 1,370 | 1,306 | 1,234 | 1,464 | 1,307 |
| Cash Equivalents | 9.8% | 1,282 | 1,168 | 881 | 839 | 711 | 491 | 591 | 672 | 891 | 2,098 | 1,058 | 742 | 786 | 702 | 637 | 795 | 638 | 547 | 310 | 499 | 485 |
| Inventory | -2.6% | 657 | 675 | 714 | 728 | 862 | 985 | 1,073 | 1,138 | 1,251 | 115 | 95.00 | 91.00 | 93.00 | 86.00 | 79.00 | 71.00 | 69.00 | 61.00 | 53.00 | 43.00 | 46.00 |
| Net PPE | - | - | - | - | - | - | - | - | - | - | 124 | 128 | 128 | 128 | 130 | 132 | 129 | 127 | 113 | 200 | 198 | 188 |
| Goodwill | 1.1% | 1,743 | 1,723 | 1,693 | 1,593 | 1,688 | 1,782 | 1,828 | 1,850 | 1,888 | 938 | 958 | 937 | 918 | 909 | 920 | 907 | 925 | 920 | 928 | 932 | 936 |
| Current Liabilities | 4.0% | 945 | 909 | 933 | 813 | 705 | 737 | 809 | 735 | 881 | 752 | 654 | 642 | 410 | 396 | 364 | 390 | 369 | 414 | 345 | 341 | 348 |
| LT Debt, Current | 0% | 31.00 | 31.00 | 31.00 | 31.00 | 31.00 | 31.00 | 31.00 | 31.00 | 249 | 249 | 246 | 244 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 |
| LT Debt, Non Current | -0.1% | 5,687 | 5,690 | 5,693 | 5,696 | 5,990 | 5,993 | 6,019 | 6,247 | 6,489 | 1,853 | 1,849 | 1,844 | 2,070 | 1,577 | 1,574 | 1,571 | 1,568 | 1,565 | 1,563 | 1,561 | 1,558 |
| Shareholder's Equity | 5.7% | 3,526 | 3,335 | 3,086 | 2,745 | 3,201 | 3,608 | 3,965 | 3,938 | 4,131 | 3,798 | 3,660 | 3,377 | 3,142 | 2,809 | 3,111 | 3,054 | 2,983 | 2,730 | 2,757 | 3,027 | 2,870 |
| Retained Earnings | 1.1% | 812 | 803 | 734 | 974 | 994 | 959 | 830 | 866 | 918 | 1,282 | 1,160 | 1,026 | 878 | 771 | 1,068 | 1,104 | 1,022 | 820 | 846 | 1,128 | 1,000 |
| Additional Paid-In Capital | 1.9% | 3,580 | 3,512 | 3,477 | 3,388 | 3,312 | 3,239 | 3,535 | 3,470 | 3,403 | 2,695 | 2,634 | 2,538 | 2,499 | 2,294 | 2,266 | 2,209 | 2,171 | 2,131 | 2,114 | 2,078 | 2,037 |
| Shares Outstanding | 0.8% | 64.00 | 63.00 | 63.00 | 63.00 | 62.00 | 62.00 | 62.00 | 61.00 | 59.00 | 56.00 | 56.00 | 56.00 | 55.00 | 56.00 | 56.00 | 57.00 | 57.00 | 57.00 | 58.00 | 60.00 | 60.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -0.5% | 1,377 | 1,384 | 1,272 | 1,108 | 964 | 702 | 779 | 787 | 771 | 912 | 900 | 801 | 881 | 847 | 776 | 907 | 791 | 834 | 799 | 785 | 753 |
| Share Based Compensation | 3.4% | 236 | 228 | 222 | 214 | 210 | 205 | 189 | 167 | 144 | 127 | 121 | 116 | 114 | 112 | 111 | 111 | 108 | 106 | 102 | 103 | 105 |
| Cashflow From Investing | 0.8% | -410 | -413 | -446 | -131 | -163 | -5,986 | -5,212 | -5,128 | -5,381 | -210 | -1,007 | -1,239 | -1,119 | -381 | -155 | 44.00 | 12.00 | -176 | -394 | -466 | -477 |
| Cashflow From Financing | -37.2% | -395 | -288 | -529 | -795 | -971 | 3,681 | 3,971 | 4,273 | 4,716 | 694 | 528 | 384 | 388 | -311 | -293 | -652 | -646 | -561 | -479 | -72.66 | -31.66 |
| Buy Backs | - | 127 | - | 0.00 | 0.00 | 0.00 | - | - | - | - | 7.00 | 147 | 257 | 277 | 329 | 301 | 638 | 639 | 600 | 524 | 119 | 124 |
JAZZ Income Statement
2023-06-30CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Total revenues | $ 957,317 | $ 932,878 | $ 1,850,129 | $ 1,746,599 |
| Operating expenses: | ||||
| Cost of product sales (excluding amortization of acquired developed technologies) | 97,537 | 124,208 | 226,181 | 239,492 |
| Selling, general and administrative | 340,844 | 366,473 | 638,761 | 675,286 |
| Research and development | 209,238 | 139,047 | 398,648 | 269,028 |
| Intangible asset amortization | 152,062 | 148,456 | 301,848 | 320,550 |
| Acquired in-process research and development | 0 | 69,148 | 1,000 | 69,148 |
| Total operating expenses | 799,681 | 847,332 | 1,566,438 | 1,573,504 |
| Income from operations | 157,636 | 85,546 | 283,691 | 173,095 |
| Interest expense, net | (73,470) | (63,189) | (147,617) | (133,873) |
| Foreign exchange gain (loss) | (2,382) | (1,343) | 811 | (11,883) |
| Income before income tax benefit and equity in loss of investees | 81,784 | 21,014 | 136,885 | 27,339 |
| Income tax benefit | (24,323) | (16,112) | (39,647) | (15,576) |
| Equity in loss of investees | 1,669 | 2,461 | 2,674 | 6,603 |
| Net income | $ 104,438 | $ 34,665 | $ 173,858 | $ 36,312 |
| Net income per ordinary share: | ||||
| Basic (in dollars per share) | $ 1.63 | $ 0.56 | $ 2.73 | $ 0.58 |
| Diluted (in dollars per share) | $ 1.52 | $ 0.55 | $ 2.55 | $ 0.57 |
| Weighted-average ordinary shares used in per share calculations - basic (in shares) | 63,991 | 62,436 | 63,744 | 62,152 |
| Weighted-average ordinary shares used in per share calculations - diluted (in shares) | 73,540 | 63,431 | 73,657 | 63,171 |
| Product sales, net | ||||
| Revenues: | ||||
| Total revenues | $ 946,987 | $ 928,300 | $ 1,831,206 | $ 1,738,137 |
| Royalties and contract revenues | ||||
| Revenues: | ||||
| Total revenues | $ 10,330 | $ 4,578 | $ 18,923 | $ 8,462 |
JAZZ Balance Sheet
2023-06-30CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 1,282,304 | $ 881,482 |
| Investments | 80,000 | 0 |
| Accounts receivable, net of allowances | 610,389 | 651,493 |
| Inventories | 657,214 | 714,061 |
| Prepaid expenses | 107,490 | 91,912 |
| Other current assets | 272,458 | 267,192 |
| Total current assets | 3,009,855 | 2,606,140 |
| Property, plant and equipment, net | 229,264 | 228,050 |
| Operating lease assets | 69,040 | 73,326 |
| Intangible assets, net | 5,705,777 | 5,794,437 |
| Goodwill | 1,742,675 | 1,692,662 |
| Deferred tax assets, net | 430,086 | 376,247 |
| Deferred financing costs | 7,865 | 9,254 |
| Other non-current assets | 65,978 | 55,139 |
| Total assets | 11,260,540 | 10,835,255 |
| Current liabilities: | ||
| Accounts payable | 98,428 | 90,758 |
| Accrued liabilities | 748,304 | 803,255 |
| Current portion of long-term debt | 31,000 | 31,000 |
| Income taxes payable | 67,529 | 7,717 |
| Deferred revenue | 4 | 463 |
| Total current liabilities | 945,265 | 933,193 |
| Long-term debt, less current portion | 5,686,646 | 5,693,341 |
| Operating lease liabilities, less current portion | 65,547 | 71,838 |
| Deferred tax liabilities, net | 910,724 | 944,337 |
| Other non-current liabilities | 126,683 | 106,812 |
| Commitments and contingencies (Note 9) | ||
| Shareholders’ equity: | ||
| Ordinary shares | 6 | 6 |
| Non-voting euro deferred shares | 55 | 55 |
| Capital redemption reserve | 473 | 472 |
| Additional paid-in capital | 3,580,115 | 3,477,124 |
| Accumulated other comprehensive loss | (866,823) | (1,125,509) |
| Retained earnings | 811,849 | 733,586 |
| Total shareholders’ equity | 3,525,675 | 3,085,734 |
| Total liabilities and shareholders’ equity | $ 11,260,540 | $ 10,835,255 |
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.